Ticagrelor is a P2Y12 receptor antagonist that does not require metabolic activation. Compared to clopidogrel, it produces faster, more consistent antiplatelet effect because of which pharmacological properties?

• A Ticagrelor is a direct-acting, reversible, allosteric P2Y12 antagonist that does not require hepatic bioactivation via CYP2C19, eliminating pharmacogenomic variability (poor metabolisers) and drug interactions ✓
• B Ticagrelor binds P2Y12 irreversibly with higher affinity than clopidogrel's active thiolactone metabolite
• C Ticagrelor also inhibits P2Y1 receptors in addition to P2Y12, providing dual pathway ADP blockade
• D Ticagrelor is a prodrug activated by platelet esterases to its active thiol form, bypassing hepatic CYP metabolism

Explanation

Clopidogrel requires two-step hepatic bioactivation via CYP2C19 to generate its active thiol metabolite, which then irreversibly modifies the P2Y12 receptor's cysteine residues. Patients who are CYP2C19 poor metabolisers (~25–30% of East Asians, ~2–4% of Caucasians) have reduced clopidogrel activation, leading to inadequate platelet inhibition and higher rates of stent thrombosis ('clopidogrel hyporesponders'). Ticagrelor is a directly acting small molecule that binds P2Y12 at an allosteric site (not the ADP binding site) in a reversible manner, bypassing hepatic bioactivation entirely. This provides more consistent, faster platelet inhibition with quicker offset — the latter being advantageous when urgent surgery is needed.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.